IFRX -

QQQ ()

DIA ()

SPY ()

TLT ()

GLD ()

Previous Close

$ na

Open

Bid

-- x --

Ask

-- x --

Day's Range

-- - --

52 Week Range

-- - --

Volume

Average Volume

Market Cap

Beta (5Y Monthly)

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

-- (--)

Last Ex-Dividend

1y Target Est

TBD --

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type	Report Link
No Data found

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

InflaRx Regains Nasdaq Compliance
09/12/2025 12:36:51

InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement s...

top-4-biotech-stocks-set-for-a-breakout-momentum-scores-surge

Top 4 Biotech Stocks Set For A Breakout: M...
09/08/2025 09:59:39

Several biotech stocks are showing renewed strength over the past week, with their Momentum scores soaring in Benzinga's Ed...

HC Wainwright & Co. Assumes InflaRx at Buy...
09/02/2025 10:49:28

HC Wainwright & Co. analyst Matthew Keller assumes InflaRx (NASDAQ:IFRX) with a Buy rating and announces Price Target of...

12 Health Care Stocks Moving In Friday's I...
08/29/2025 17:05:57

12 Health Care Stocks Moving In Thursday's...
08/28/2025 17:06:35

InflaRx Q2 EPS $(0.24) Misses $(0.17) Esti...
08/07/2025 11:36:47

InflaRx (NASDAQ:IFRX) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.17) by ...

Earnings Scheduled For August 7, 2025
08/07/2025 08:33:15

InflaRx Receives Nasdaq Deficiency Notice ...
07/11/2025 20:15:48

Oppenheimer Maintains Outperform on InflaR...
05/29/2025 16:35:56

Oppenheimer analyst Andreas Argyrides maintains InflaRx (NASDAQ:IFRX) with a Outperform and lowers the price target from $6 ...

crude-oil-gains-2-macys-lowers-earnings-forecast

Crude Oil Gains 2%; Macy's Lowers Earnings...
05/28/2025 16:19:22

inflarx-ends-lead-asset-development-after-failed-study-for-rare-and-painful-skin-disease

InflaRx Ends Lead Asset Development After ...
05/28/2025 15:00:12

InflaRx ends its Phase 3 trial of vilobelimab in pyoderma gangrenosum and shifts focus to INF904 amid efforts to extend its cas...

us-stocks-gain-abercrombie--fitch-posts-upbeat-earnings

US Stocks Gain; Abercrombie & Fitch Posts ...
05/28/2025 13:56:36

why-box-shares-are-trading-higher-by-12-here-are-20-stocks-moving-premarket

Why Box Shares Are Trading Higher By 12%; ...
05/28/2025 09:22:42

InflaRx Halts Vilobelimab Phase 3 Trial In...
05/28/2025 06:36:03

the Independent Data Monitoring Committee (IDMC) conducting the unblinded interim analysis for the Phase 3 trial for vilobelima...

this-centessa-pharmaceuticals-analyst-begins-coverage-on-a-bullish-note-here-are-top-2-initiations-for-thursday

This Centessa Pharmaceuticals Analyst Begi...
05/08/2025 14:42:35

Oppenheimer Initiates Coverage On InflaRx ...
05/08/2025 14:15:34

Oppenheimer analyst Andreas Argyrides initiates coverage on InflaRx (NASDAQ:IFRX) with a Outperform rating and announces Pri...

InflaRx Q1 EPS $(0.14) Beats $(0.19) Estimate
05/07/2025 11:36:54

InflaRx (NASDAQ:IFRX) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.19) by 26...

Earnings Scheduled For May 7, 2025
05/07/2025 08:33:08

Preview: InflaRx's Earnings
05/06/2025 21:01:42

Cantor Fitzgerald Initiates Coverage On In...
04/29/2025 12:50:53

Cantor Fitzgerald analyst Steven Seedhouse initiates coverage on InflaRx (NASDAQ:IFRX) with a Overweight rating and announce...

IFRX

News

OPINIONS

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

Search Symbol

Create a Free Account Sign in to your Account Reset Password

IFRX

Create a Free Account Sign in to your Account Reset Password

News

OPINIONS

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

Add/Delete Symbol to your Portfolio